Current and historical daily PE Ratio for BioMerieux SA (
) from 2020 to Jun 18 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. BioMerieux stock (WBO:BIM) PE ratio as of Jun 18 2024 is 30.05.
More Details
BioMerieux SA (WBO:BIM) PE Ratio (TTM) Chart
BioMerieux SA (WBO:BIM) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 965
- 1
- 2
- 3
- 4
- 5
- 6
- 11
BioMerieux PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-18 | 30.1 | 2024-04-15 | 35.0 |
2024-06-17 | 30.1 | 2024-04-12 | 35.3 |
2024-06-14 | 30.2 | 2024-04-11 | 34.6 |
2024-06-13 | 30.5 | 2024-04-10 | 34.5 |
2024-06-12 | 30.5 | 2024-04-09 | 34.1 |
2024-06-11 | 30.6 | 2024-04-08 | 32.9 |
2024-06-10 | 30.8 | 2024-04-05 | 32.9 |
2024-06-07 | 31.5 | 2024-04-04 | 32.9 |
2024-06-06 | 31.8 | 2024-04-03 | 34.0 |
2024-06-05 | 32.1 | 2024-04-02 | 33.8 |
2024-06-04 | 31.9 | 2024-03-29 | 33.6 |
2024-06-03 | 31.2 | 2024-03-28 | 33.6 |
2024-05-31 | 31.2 | 2024-03-27 | 33.6 |
2024-05-30 | 31.1 | 2024-03-26 | 33.4 |
2024-05-29 | 31.1 | 2024-03-25 | 33.1 |
2024-05-28 | 31.6 | 2024-03-22 | 33.0 |
2024-05-27 | 31.8 | 2024-03-21 | 32.5 |
2024-05-24 | 31.4 | 2024-03-20 | 32.5 |
2024-05-23 | 31.4 | 2024-03-19 | 32.4 |
2024-05-22 | 33.2 | 2024-03-18 | 32.6 |
2024-05-21 | 33.2 | 2024-03-15 | 33.0 |
2024-05-20 | 33.2 | 2024-03-14 | 32.4 |
2024-05-17 | 33.2 | 2024-03-13 | 32.9 |
2024-05-16 | 33.2 | 2024-03-12 | 32.9 |
2024-05-15 | 33.2 | 2024-03-11 | 32.8 |
2024-05-14 | 33.2 | 2024-03-08 | 33.0 |
2024-05-13 | 33.2 | 2024-03-07 | 33.0 |
2024-05-10 | 33.1 | 2024-03-06 | 33.7 |
2024-05-09 | 33.3 | 2024-03-05 | 34.2 |
2024-05-08 | 33.3 | 2024-03-04 | 34.3 |
2024-05-07 | 33.1 | 2024-03-01 | 33.9 |
2024-05-06 | 32.8 | 2024-02-29 | 34.5 |
2024-05-03 | 33.0 | 2024-02-28 | 34.5 |
2024-05-02 | 33.0 | 2024-02-27 | 34.3 |
2024-04-30 | 33.8 | 2024-02-26 | 35.0 |
2024-04-29 | 33.7 | 2024-02-23 | 34.8 |
2024-04-26 | 33.3 | 2024-02-22 | 35.1 |
2024-04-25 | 33.3 | 2024-02-21 | 34.5 |
2024-04-24 | 33.9 | 2024-02-20 | 34.6 |
2024-04-23 | 34.1 | 2024-02-19 | 34.2 |
2024-04-22 | 34.3 | 2024-02-16 | 34.3 |
2024-04-19 | 34.3 | 2024-02-15 | 33.8 |
2024-04-18 | 34.3 | 2024-02-14 | 33.5 |
2024-04-17 | 34.3 | 2024-02-13 | 34.1 |
2024-04-16 | 34.3 | 2024-02-12 | 34.0 |
BioMerieux SA (WBO:BIM) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
BioMerieux SA
ISIN : FR0013280286
Share Class Description:
WBO:BIM: Ordinary SharesCompare
Compare
Traded in other countries / regions
BIM.France0RUG.UKBMXMF.USAEYWN.GermanyBIM.Austria IPO Date
2020-09-17Description
BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.